Related Experiment Video

Updated: Oct 28, 2025

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

656

Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia

Maura Argenziano1, Chiara Tortora1, Alessandra Di Paola2

  • 1Department of Woman, Child and General and Specialist Surgery, University of Campania Luigi Vanvitelli, Naples 80138, Italy.

Oncotarget
|July 15, 2021
PubMed

Insights

Eltrombopag (ELT) and deferasirox (DFX) show potential in treating pediatric acute myeloid leukemia (AML) by targeting iron metabolism. ELT enhances cytarabine

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Pediatric acute myeloid leukemia (AML) has a poor prognosis, with current treatments like cytarabine and anthracycline yielding ~50% survival.
  • Iron metabolism is crucial in cancer progression, suggesting iron-targeting agents as a novel therapeutic strategy.
  • Deferasirox (DFX) and Eltrombopag (ELT) exhibit anticancer properties, with ELT also acting as an iron chelator.

Purpose of the Study:

  • To compare the anticancer effects of cytarabine, DFX, and ELT in a pediatric AML cell line.
  • To explore novel therapeutic strategies for pediatric AML by targeting iron metabolism.
  • To investigate the potential of ELT and DFX as antineoplastic agents.

Main Methods:

  • Utilized the pediatric AML cell line THP-1 for comparative drug effect analysis.
  • Assessed the impact of cytarabine, DFX, and ELT on intracellular iron concentrations.
  • Evaluated the combined effects of ELT and cytarabine on antineoplastic activity.

Main Results:

  • Both ELT and DFX effectively reduce intracellular iron levels by inhibiting uptake and promoting release.
  • ELT demonstrated an enhancement of cytarabine's antineoplastic activity in the pediatric AML cell line.
  • DFX also showed antiproliferative effects, suggesting its potential as an antiblastic drug.

Conclusions:

  • ELT and DFX represent promising therapeutic agents for pediatric AML by modulating iron metabolism.
  • ELT may enhance the efficacy of standard chemotherapy, offering a potential strategy to improve treatment outcomes.
  • Further research is warranted to elucidate the precise mechanisms of action for ELT and DFX in pediatric AML.

Keywords:
acute monocytic leukemiacancerdeferasiroxeltrombopagiron chelation

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

379

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
44
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
46
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
593
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
48